Pulmonx Co. (NASDAQ:LUNG) Receives Average Recommendation of “Moderate Buy” from Brokerages

Pulmonx Co. (NASDAQ:LUNG) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $14.67.

A number of brokerages recently commented on LUNG. Canaccord Genuity Group raised their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus decreased their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Wells Fargo & Company cut their price objective on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st.

Insider Buying and Selling

In other Pulmonx news, CEO Steven S. Williamson purchased 14,245 shares of Pulmonx stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, with a total value of $97,435.80. Following the completion of the acquisition, the chief executive officer now owns 219,531 shares of the company’s stock, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Steven S. Williamson bought 14,245 shares of Pulmonx stock in a transaction on Tuesday, August 20th. The shares were bought at an average price of $6.84 per share, with a total value of $97,435.80. Following the acquisition, the chief executive officer now directly owns 219,531 shares in the company, valued at approximately $1,501,592.04. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel David Aaron Lehman sold 5,765 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.69, for a total value of $38,567.85. Following the transaction, the general counsel now owns 203,348 shares in the company, valued at $1,360,398.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,351 shares of company stock valued at $361,494 in the last quarter. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Pulmonx

Several hedge funds have recently bought and sold shares of LUNG. Squarepoint Ops LLC increased its stake in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock valued at $916,000 after buying an additional 104,432 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Pulmonx during the second quarter valued at approximately $477,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in Pulmonx by 141.6% in the second quarter. Cubist Systematic Strategies LLC now owns 109,105 shares of the company’s stock worth $692,000 after purchasing an additional 63,945 shares during the period. Finally, Sofinnova Investments Inc. bought a new position in Pulmonx during the 2nd quarter valued at $382,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Stock Up 0.3 %

Shares of NASDAQ LUNG opened at $6.27 on Tuesday. Pulmonx has a 1 year low of $5.46 and a 1 year high of $14.84. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. The business has a 50-day moving average of $7.24 and a two-hundred day moving average of $7.25.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.02. The firm had revenue of $20.78 million during the quarter, compared to analysts’ expectations of $20.23 million. Pulmonx had a negative return on equity of 51.92% and a negative net margin of 72.01%. Research analysts anticipate that Pulmonx will post -1.64 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.